IOBT will succeed

by Retirement Advisor | Oct 11, 2022 | Resources

https://external-preview.redd.it/Fn3-rVPZkbxPC6KBdv65i2zmroORIfcMAcb2gyiXkXE.jpg?auto=webp&s=6002d1965bc1d5d6b000d1c468ed09fa169d760f

Io biotech IOBT

Several candidates in the upcoming years

Currently FDA breakthrough designation on phase 3 cancer vaccine in treatment of melanoma.

Spinoff IPO directly out of leading danish governmental cancer institute (herlev hospital)

Founders of IOBT is mads hald and inge marie svane (the absolute top 2 scientist in this Area for the last 2 decades) currently hired as clinical advisors also.

Magnificent results in phase 2 trial triggered fda breakthrough designation published in nature medicin

Inge marie svane leading the phase 3.

Backed up from the start by Novo Nordisk and Lundbeckfonden

Long cash runway

Big spread on bid vs. Ask. The stock moves 5 % everytime 100 shares Are sold or bought. (Will moon when data begins to enter from phase 3 end of this year)

IO BIOTECH holds all commercial right to the io102 / io103 which is currently phase 3.

Big cooperation with Merck in the current phase 3.

IO biotech is the only company which is this far into getting fda approval in this current kind of treatment.

The method and treatment is unique and patented.

Alone in the us 100.000 New cases of melanoma every year.

Currently undervalued stockprise by 10x compared to expected marketvalue the first phase 3 goes though
Links: https://www.iobiotech.com/2021/12/09/io-biotech-announces-publication-of-phase-1-2-melanoma-clinical-trial-results-in-nature-medicine/

https://www.bloomberg.com/press-releases/2022-05-18/io-biotech-announces-initiation-of-phase-3-combination-trial-of-io102-io103-and-keytruda-pembrolizumab-as-first-line

https://research.regionh.dk/da/persons/inge-marie-svane(6f7bc939-b88e-4435-8b6d-7cb52c635f35).html

https://www.iobiotech.com/team/professor-md-ph-d-inge-marie-svane/

View Reddit by If_I_fits_I_sits_ – View Source